Evidence map›Paper›PMID 41286778›Full record

ArticleBMC cancer2025

MIR4435-2HG: a key player in the novel lncRNA prognostic signatures causes early metastasis after tumor resection and poor prognosis for esophageal squamous cell carcinoma.

Pengju Qi, Shuhua Huo, Wenchao Wu, Tengfei Zhang, Wenqian Yang, Jiaping Tang, Yuzhen Liu, Baosheng Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pengju QiDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Shuhua HuoDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Wenchao WuDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Tengfei ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Wenqian YangDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Jiaping TangDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China.
Yuzhen LiuDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China. yuzhenliu@xxmu.edu.cn.
Baosheng ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Henan Medical University, Weihui, Xinxiang, Henan Province, 453100, China. drbszhao@xxmu.edu.cn.

Funding

Henan Provincial Joint Key Medical Science and Technology Research Project SBGJ202102188Henan Provincial Medical Science and Technology Tackling Plan Joint Construction Project LHGJ20230507Key Technologies R&D Program of Science and Technology Commission Foundation of Henan Provence 242102311124
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is a major histopathological type of esophageal cancer. Tumor metastasis is a critical factor that dramatically worsens the prognosis, leading to a decline in survival rates. Understanding the molecular mechanisms underlying metastasis and identifying reliable biomarkers to predict metastasis susceptibility are essential for improving patient outcomes. This study aims to explore the role of lncRNA MIR4435-2HG in ESCC metastasis susceptibility and its potential as a prognostic biomarker.

methodsWe conducted a genome-wide analysis of gene expression in ESCC tissues from four patients with similar clinical characteristics but divergent prognoses to identify differentially expressed lncRNAs and mRNAs. We focused on the lncRNA MIR4435-2HG, examining its expression levels in correlation with clinical outcomes and its role in the PI3K-Akt pathway through in vitro experiments and bioinformatics analysis.

resultsDifferential expression analysis identified 2000 prognosis-related lncRNAs, with MIR4435-2HG showing significant upregulation in tumor tissues of patients with poor prognosis. High expression levels of MIR4435-2HG were associated with advanced tumor stage and short-term survival. The key lncRNA-miRNA-mRNA axes in the prognostic sub-network offer insights into the interactions most relevant to cancer prognosis. The results of in vitro experiments and enrichment analysis suggested that MIR4435-2HG promotes tumor proliferation and metastasis by activating the PI3K-Akt pathway.

conclusionMIR4435-2HG may represent a potential biomarker associated with metastasis and poor prognosis. Its possible involvement in the PI3K-Akt pathway warrants further validation and investigation in larger clinical cohorts.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaMicroRNAsRNA, Long NoncodingCell Line, TumorCell ProliferationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm MetastasisPhosphatidylinositol 3-KinasesPrognosisBiomarkers, TumorMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingBiomarkerESCCMetastasisMIR4435-2HGPI3K-Akt signaling pathway

Identifiers

PMID41286778
PMCPMC12817812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.